NSCLC
Oncology · 2006–2026
79decisions
28medicines
48carried consumer input
213individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| amivantamab Treatment of patients with epidermal growth factor receptor gene mutated (EGFRm) locally advanced/metastatic non-small cell lung cancer (NSCLC) where the… | Mar 2026 | Recommended with restriction | 18 individuals Lung Foundation Australia · Thoracic Group |
| osimertinib First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with evidence of an activating epidermal growth factor… | Sep 2025 | Recommended with restriction | no section in document |
| osimertinib Treatment of patients with unresectable locally advanced (Stage III) epidermal growth factor receptor (EGFR) pathogenic variant positive non-small cell lung… | Jul 2025 | Recommended with restriction | input received Thoracic Oncology Group · Medical Oncology Group Australia · Lung Foundation Australia · Rare Cancers Australia |
| osimertinib First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with evidence of activating epidermal growth factor… | May 2025 | Not recommended | input received Lung Foundation Australia · Rare Cancer Australia · Thoracic Oncology Group · Medical Oncology Group |
| amivantamab; lazertinib First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with evidence in tumour material of an activating… | Mar 2025 | Not recommended | 74 individuals Rare Cancers Australia · Lung Foundation Australia · Medical Oncology Group |
| dabrafenib and trametinib Treatment of adult patients with BRAF V600E mutation positive advanced or metastatic (Stage IV) non-small cell lung cancer (NSCLC). | Mar 2025 | Recommended with restriction | 3 individuals Lung Foundation Australia · Rare Cancers Australia · Rare Caners Australia · Medical Oncology Group |
| encorafenib Advanced or metastatic non-small cell lung cancer (Stage IV NSCLC) with a BRAF V600E mutation who have not received prior systemic treatment in the metastatic… | Nov 2025 | Recommended with restriction | 1 individuals Lung Foundation Australia · Thoracic Group · Rare Cancers Australia · Medical Oncology Group |
| selpercatinib Treatment of advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adults. | Jul 2024 | Recommended with restriction | input received Rare Cancers Australia · Lung Foundation Australia · Medical Oncology Group |
| atezolizumab Subcutaneous injection formulation for five oncology indications: locally advanced or metastatic NSCLC, stage IV (metastatic) NSCLC, extensive-stage small cell… | Mar 2024 | Recommended with restriction | input received Rare Cancers Australia · Lung Foundation Australia |
| bevacizumab Multiple cancer indications: metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small… | Mar 2024 | Recommended | 1 individuals Medical Oncology Group |
| nivolumab Neoadjuvant treatment of surgically-resectable non-small cell lung cancer (NSCLC) in patients with node-positive disease or tumours ≥4 cm. | Mar 2024 | Recommended with restriction | input received Lung Foundation Australia · Medical Oncology Group · Society for Immunotherapy of Cancer |
| nivolumab Perioperative treatment of patients with resectable non-small cell lung cancer (NSCLC) comprising neoadjuvant nivolumab plus platinum-doublet chemotherapy… | Dec 2024 | Not recommended | input received Rare Cancers Australia · Lung Foundation Australia · Medical Oncology Group |
| amivantamab Treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation positive locally advanced or metastatic non-small cell… | Nov 2024 | Recommended with restriction | 14 individuals Rare Cancers Australia · Lung Foundation Australia · Medical Oncology Group |
| mobocertinib Treatment of adults with locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) harbouring epidermal growth factor… | Jul 2023 | Recommended with restriction | 2 individuals Rare Cancers Australia · Lung Foundation Australia · Medical Oncology Group |
| nivolumab Neoadjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC) in combination with platinum-doublet chemotherapy. | Jul 2023 | Recommended with restriction | input received Lung Foundation Australia · Medical Oncology Group |
| nivolumab Neoadjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC) (tumours ≥4 cm or node positive) in combination with platinum-based… | Mar 2023 | Not recommended | input received Lung Foundation Australia · Rare Cancers Australia · Medical Oncology Group |
| pemetrexed Patients with malignant pleural mesothelioma and patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell… | Mar 2023 | Recommended with restriction | input received Lung Foundation Australia |
| cemiplimab First-line treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC) with no evidence of EGFR, ALK, or ROS1 aberrations, in… | Nov 2023 | Recommended with restriction | input received Lung Foundation Australia |
| osimertinib Adjuvant therapy after surgical resection in patients with Stage IB to IIIA EGFR mutation-positive non-small cell lung cancer (NSCLC). | Nov 2023 | Recommended with restriction | 1 individuals Lung Foundation Australia |
| atezolizumab Adjuvant treatment in patients with Stage II-IIIA programmed cell death ligand-1 (PD-L1) ≥50% positive non-small cell lung cancer (NSCLC) following complete… | Jul 2022 | Recommended | input received Lung Foundation Australia · Medical Oncology Group · Lung Foundation |
| durvalumab Treatment of unresectable Stage III non-small cell lung cancer (NSCLC) in patients who have received platinum-based chemoradiation therapy and whose disease… | Mar 2022 | Recommended | input received Lung Foundation Australia · Rare Cancers Australia |
| sotorasib Treatment of patients with non-squamous or not otherwise specified Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)… | Mar 2022 | Recommended with restriction | input received Medical Oncology Group |
| mobocertinib Adults with epidermal growth factor receptor exon 20 insertion (EGFR ex20ins) positive locally advanced or metastatic (Stage IIIB/IV) non-small cell lung… | Nov 2022 | Not recommended | input received Rare Cancers Australia · Lung Foundation Australia · Medical Oncology Group |
| lorlatinib Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement in… | Jul 2021 | Deferred | input received Medical Oncology Group |
| bevacizumab Treatment of non-small cell lung cancer (NSCLC) in combination with platinum-doublet chemotherapy, and other cancer indications including ovarian cancer,… | Mar 2021 | Recommended with restriction | input received Lung Foundation Australia |
| nivolumab Non-small cell lung cancer (NSCLC) following progression or after prior chemotherapy (2L NSCLC) | Mar 2021 | Noted | none received |
| lorlatinib Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement in… | Dec 2021 | Deferred | input received Medical Oncology Group |
| bevacizumab Biosimilar to Avastin; indicated for the same indications as the reference bevacizumab (includes first-line treatment of Stage IV non-squamous non-small cell… | Nov 2021 | Recommended with restriction | unclear |
| cemiplimab First-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with high PD-L1 expression (tumour proportion score ≥50%), who are EGFR… | Nov 2021 | Recommended with restriction | 2 individuals Medical Oncology Group · Lung Foundation Australia · Rare Cancers Australia |
| tepotinib Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations (METex14sk). | Nov 2021 | Deferred | input received Lung Foundation · Medical Oncology Group |
| osimertinib First-line treatment of locally advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer with epidermal growth factor receptor mutation… | Jul 2020 | Recommended with restriction | unclear |
| nivolumab plus ipilimumab First-line treatment of previously untreated Stage IV (metastatic) non-small cell lung cancer in patients with no EGFR or ALK gene rearrangement, in… | Nov 2020 | Recommended with restriction | input received Lung Foundation · Medical Oncology Group |
| pembrolizumab Previously untreated Stage IV non-small cell lung cancer without targetable mutations. | Aug 2019 | Recommended with restriction | no section in document |
| durvalumab Stage III unresectable non-small cell lung cancer (NSCLC) in patients who have not progressed after platinum-based chemoradiation therapy. | Jul 2019 | Not recommended | unclear |
| pembrolizumab First-line treatment of patients with Stage IV non-squamous non-small cell lung cancer (NSCLC) who are EGFR wild-type, negative for ALK or ROS1 gene… | Jul 2019 | Recommended with restriction | 2 individuals Lung Foundation Australia · Lung Foundation · Medical Oncology Group |
| alectinib Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) with ALK gene rearrangement. | Mar 2019 | Not recommended | 3 individuals |
| atezolizumab Treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) in combination with bevacizumab and platinum-doublet chemotherapy. Two… | Mar 2019 | Recommended with restriction | input received Lung Foundation Australia · Medical Oncology Group |
| pembrolizumab First-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with PD-L1 tumour proportion score (TPS) ≥50%. | Mar 2019 | Noted | no section in document |
| alectinib; crizotinib; ceritinib Increase in the number of repeats (from 1 to 3) for the treatment of patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung… | Nov 2019 | Recommended with restriction | no section in document |
| atezolizumab Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), and first-line treatment of stage IV metastatic non-squamous NSCLC… | Nov 2019 | Recommended with restriction | 1 individuals Lung Foundation Australia |
| durvalumab Treatment of unresectable Stage III non-small cell lung cancer (NSCLC) for patients whose disease has not progressed following chemoradiation therapy (CRT). | Nov 2019 | Recommended with restriction | 2 individuals Medical Oncology Group |
| osimertinib Locally advanced or metastatic EGFR T790M mutation positive non-small cell lung cancer (NSCLC) in patients who have progressed on or after prior treatment with… | Jul 2018 | Deferred | 29 individuals Rare Cancers Australia · Lung Foundation · Medical Oncology Group |
| pembrolizumab First-line treatment of metastatic (Stage IV) non-small cell lung cancer (NSCLC) in patients whose tumours do not have an activating EGFR gene mutation or ALK… | Jul 2018 | Recommended with restriction | 10 individuals Medical Oncology Group |
| pembrolizumab First-line treatment of patients with metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumours do not have an activating EGFR gene mutation or… | Mar 2018 | Deferred | 4 individuals Lung Foundation Australia · Medical Oncology Group |
| durvalumab Treatment of Stage III unresectable non-small cell lung cancer (NSCLC) in patients who have not progressed after platinum-based chemoradiation therapy, as… | Nov 2018 | Not recommended | input received Medical Oncology Group |
| osimertinib Treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) who have progressed on or after prior… | Nov 2018 | Noted | 5 individuals Medical Oncology Group |
| pembrolizumab First-line treatment of patients with Stage IV non-squamous non-small cell lung cancer (NSCLC) with EGFR wild-type and ALK translocation negative status in… | Nov 2018 | Not recommended | 2 individuals Medical Oncology Group |
| crizotinib Treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). | Mar 2017 | Noted | none received |
| nivolumab Second-line treatment of squamous cell and non-squamous cell non-small cell lung cancer (NSCLC) in patients with advanced disease who have failed… | Mar 2017 | Recommended with restriction | none received |
| pembrolizumab First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients without activating EGFR gene mutation or ALK gene… | Mar 2017 | Recommended with restriction | 11 individuals Medical Oncology Group |
| atezolizumab Locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have disease progression on or after prior platinum-based chemotherapy. | Nov 2017 | Recommended with restriction | 2 individuals Medical Oncology Group |
| crizotinib Treatment of patients with locally advanced (Stage IIIB) or metastatic (Stage IV) ROS1-positive NSCLC who have disease progression on or following treatment… | Nov 2017 | Deferred | 7 individuals Rare Cancers Australia · Medical Oncology Group |
| osimertinib Locally advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) in patients with T790M mutation-positive disease following… | Nov 2017 | Recommended with restriction | 19 individuals Rare Cancers Australia · Medical Oncology Group |
| pembrolizumab First-line treatment of patients with metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumours do not have an activating EGFR gene mutation or… | Nov 2017 | Deferred | input received Medical Oncology Group |
| pemetrexed Treatment of patients with locally advanced or metastatic non-small cell lung cancer (after prior platinum-based chemotherapy) and malignant pleural… | Mar 2016 | Recommended | input received Lung Foundation Australia · Lung Cancer Foundation Australia |
| pemetrexed Additional 1 g strength for treatment of patients with malignant pleural mesothelioma in combination with cisplatin, and locally advanced or metastatic… | Mar 2016 | Recommended | input received Lung Foundation Australia · Lung Cancer Foundation Australia |
| pembrolizumab Locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with high PD-L1 expression (tumour proportion score ≥50%), who have progressed… | Nov 2016 | Not recommended | input received Medical Oncology Group · Lung Foundation |
| afatinib dimaleate First or subsequent line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) characterised by exon 19 deletion mutations of the… | Jul 2015 | Not recommended | none received |
| crizotinib Treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who have disease progression following at… | Mar 2014 | Deferred | input received Medical Oncology Group |
| afatinib First-line treatment of locally advanced (stage IIIB) or metastatic (stage IV) non-squamous non-small cell lung cancer (NSCLC) in patients with evidence of… | Jul 2013 | Recommended with restriction | unclear |
| afatinib Second/third-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients without EGFR mutation status who have progressive… | Jul 2013 | Not recommended | no section in document |
| erlotinib Initial and continuing first-line treatment, as monotherapy, of locally advanced (stage IIIB) or metastatic (stage IV) non-squamous or not otherwise specified… | Jul 2013 | Recommended with restriction | unclear |
| gefitinib First-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in patients with activating mutations of the epidermal… | Jul 2013 | Noted | unclear |
| erlotinib Initial and continuing first-line treatment, as monotherapy, of locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) in… | Jul 2012 | Recommended with restriction | unclear |
| gefitinib First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with activating epidermal growth factor receptor (EGFR)… | Nov 2012 | Recommended with restriction | unclear |
| gefitinib First-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with activating mutations of the epidermal growth factor receptor… | Nov 2012 | Recommended with restriction | unclear |
| bevacizumab Initial treatment in combination with carboplatin and paclitaxel of patients with advanced or metastatic non-squamous non-small cell lung cancer with WHO… | Mar 2011 | Not recommended | unclear |
| pemetrexed disodium First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with predominantly non-squamous cell histology in combination with… | Mar 2010 | Not recommended | no section in document |
| gefitinib First-line treatment of locally advanced or metastatic non-small cell lung cancer (Stage IIb/IV NSCLC) with activating mutation in the epidermal growth factor… | Nov 2010 | Recommended with restriction | no section in document |
| pemetrexed First-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) with non-squamous cell histology in combination with cisplatin. | Mar 2009 | Recommended with restriction | no section in document |
| pemetrexed disodium First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with predominantly non-squamous cell histology in combination with… | Nov 2009 | Recommended with restriction | no section in document |
| erlotinib hydrochloride Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with WHO performance status of 3 or less following disease… | Nov 2007 | Recommended | no section in document |
| erlotinib hydrochloride Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received chemotherapy, specifically for… | Nov 2007 | Recommended | no section in document |
| pemetrexed disodium Treatment of patients with malignant pleural mesothelioma in combination with cisplatin. | Nov 2007 | Recommended with restriction | no section in document |
| erlotinib hydrochloride Treatment of patients with locally advanced or metastatic non-small cell lung cancer who have previously received chemotherapy. | Mar 2006 | Recommended | no section in document |
| vinorelbine tartrate Locally advanced or metastatic non-small cell lung cancer (NSCLC) as a single agent or in combination. | Mar 2006 | Recommended with restriction | no section in document |
| erlotinib hydrochloride Treatment of patients with locally advanced or metastatic non-small cell lung cancer who have previously received chemotherapy. | Mar 2006 | Recommended | no section in document |
| vinorelbine tartrate Locally advanced or metastatic non-small cell lung cancer (NSCLC) as monotherapy for first-line treatment in patients with unresectable Stage IIIB and IV… | Mar 2006 | Recommended with restriction | no section in document |
| erlotinib hydrochloride Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received chemotherapy. | Nov 2006 | Not recommended | no section in document |
Who spoke
Medical Oncology Group · Lung Foundation Australia · Rare Cancers Australia · Lung Foundation · Thoracic Group · Thoracic Oncology Group · Lung Cancer Foundation Australia · Rare Caners Australia · Society for Immunotherapy of Cancer · Medical Oncology Group Australia · Rare Cancer Australia
What the PBS pays
$1,949M in government benefit over 2024–25, across 355,337 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| osimertinib | $200.6M |
| nivolumab plus ipilimumab | $199M |
| durvalumab | $175.6M |
| atezolizumab | $156.8M |
| cemiplimab | $137.9M |
| nivolumab | $85.2M |
| dabrafenib and trametinib | $57.2M |
| bevacizumab | $49.4M |
| encorafenib | $37.7M |
| alectinib, crizotinib, ceritinib | $34.2M |
| alectinib | $31.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 54 technologies for this condition, recommending 38 and declining 6. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| cemiplimabCemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer | TA1165 | recommended | 2026-06 |
| amivantamabAmivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer | TA1158 | recommended restricted | 2026-05 |
| osimertinibOsimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy | TA1156 | recommended | 2026-05 |
| encorafenibEncorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer | TA1150 | recommended restricted | 2026-05 |
| nivolumabNivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer | TA1127 | recommended | 2026-02 |
| amivantamabAmivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer | TA1122 | recommended restricted | 2026-01 |
| adagrasibAdagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal) | TA1076 | terminated | 2025-07 |
| atezolizumabAtezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1071 | recommended | 2025-06 |
| tislelizumabTislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA1072 | terminated | 2025-06 |
| osimertinibOsimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer | TA1060 | recommended restricted | 2025-05 |
| tislelizumabTislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) | TA1058 | terminated | 2025-04 |
| atezolizumabAtezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) | TA1047 | terminated | 2025-03 |
Showing the 12 most recent of 54.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| capmatinibTABRECTA capmatinib (as hydrochloride) 150 mg tablet blister pack | 2026 | 4 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 48 of 59 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.